The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

Argos Therapeutics Presents Data Showing the Impact of HIV Antigen Sequence Divergence on Durable Viral Control Following Treatment With Autologous Immune Therapy
Read more

Argos Therapeutics to Present at Two Upcoming Healthcare Conferences
Read more

Argos Therapeutics to Host Post-American Society of Clinical Oncology (ASCO) Conference Call and Webcast, Monday, June 9, 2014
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC